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1. Introduction 
According to the position paper from the European Academy for Allergy and Clinical 
Immunology (EAACI) “food allergy” summarizes immune-mediated, non-toxic adverse 
reactions to foods (Figure 1)(Bruijnzeel-Koomen et al., 1995). The most common form of 
food allergy is mediated by immunoglobulin (Ig)E antibodies and reflects an immediate-
type ("Type 1 hypersensitivity") reaction, i.e. acute onset of symptoms after ingestion or 
inhalation of foods. IgE-mediated food allergy is further classified into primary (class 1) and 
secondary (class 2) food allergy. This distinction is based on clinical appearance, the 
predominantly affected group of patients (children or adults), disease-eliciting food 
allergens and the underlying immune mechanisms. Primary (class 1) or “true” food allergy 
starts in early life and often represents the first manifestation of the atopic syndrome. The 
most common foods involved are cow´s milk, hen´s egg, legumes (peanuts and soybean), 
fish, shellfish and wheat. Of note, allergens contained in these foods do not only elicit 
allergic reactions in the gastrointestinal tract but often cause or influence urticaria, atopic 
dermatitis as well as bronchial obstruction. With a few exceptions (peanut and fish) most 
children outgrow class 1 food allergy within the first 3 to 6 years of life. 
Secondary (class 2) food allergy describes allergic reactions to foods in mainly adolescent 
and adult individuals with established respiratory allergy, for example to pollen of birch, 
mugwort or ragweed. This form of food allergy is believed to be a consequence of 
immunological cross-reactivity between respiratory allergens and structurally related 
proteins in the respective foods. In principle, the recognition of homologous proteins in 
foods by IgE-antibodies specific for respiratory allergens can induce clinical symptoms. 
Foods inducing allergic reactions in the different groups of patients vary according to the 
manifested respiratory allergy. Different syndromes have been defined, such as the birch-
fruit-hazelnut-vegetable syndrome, the mugwort-celery-spice syndrome or the latex-shrimp 
syndrome. 
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Fig. 1. Classification of adverse reactions to foods according to the pathophysiology 
(Bruijnzeel-Koomen et al., 1995). Adverse reactions to foods comprise toxic and non-toxic 
reactions. The latter reactions are either non-immune-mediated or immune-mediated. IgE-
mediated reactions constitute type I hypersensitivity while non-IgE-mediated reactions are 
suspected to be mediated by IgG or IgM immune complex reactions (type III 
hypersensitivity) or cell-mediated delayed-type reactions (type IV hypersensitivity). 
2. Immune mechanisms underlying IgE-mediated allergy 
IgE-mediated allergy develops upon contact with an allergenic protein leading to 
sensitisation. The allergen is absorbed through the mucosal membrane of the respiratory or 
the gastrointestinal tract or the skin and can enter tissues through disrupted epithelium and 
gain access to antigen-presenting cells (APC), most importantly dendritic cells, which takes 
up allergen and migrate to lymph nodes. There they present small peptide fragments 
resulting from allergen processing bound to major histocompatibility complex (MHC) class 
II molecules to naïve CD4+ Th lymphocytes. Depending on key cytokines present during the 
initial interaction with APC naïve CD4+ cells differentiate into five different (and maybe 
more) “classical” effector cell subsets, Th2, Th1, Th17, Th22 cells and induced regulatory T 
(Treg) cells (Figure 2). The presence of interleukin (IL)-4 promotes T cell differentiation 
towards allergen-specific Th2 cells that produce high amounts of the signature cytokines IL-
4, IL-5, IL-9 and IL-13 but little or no interferon-γ (IFN-γ). IL-4 is the major switch factor for 
IgE synthesis in B cells. The presence of IL-12 and IL-27 during T cell priming fosters the 
differentiation of Th1 cells that produce high amounts of the signature cytokine IFN-γ, 
which is a potent antagonist of IL-4 and inhibits the differentiation of Th2 cells. Human 
Th17 cells differentiate in the presence of IL-1β and IL-23. This subset synthesizes the 
signature cytokines IL-17a, IL-17f, IL-22 and IL-21. Th17 cells are important for the defence 
against extracellular bacteria and fungi and play a role in inflamed skin in atopic dermatitis. 
Moreover, Th17 cells have been shown to be involved in initiation and augmentation of 
inflammation in the airways and in the gut mucosa. Th22 cells produce IL-22 but not IL-17 
and differentiate in the presence of IL-6 and TNF-α (Duhen et al., 2009). IL-22 is a growth 
factor for keratinocytes and Th22 cells have been considered to have a role in protective and 
regenerative epithelial cell responses (Eyerich et al., 2009). Induced Treg cells suppress the 
differentiation and effector phases of other T cell subsets either by cell-cell contact and/or 
by IL-10 and/or TGF-β. Different subsets of Treg cells have been described. So-called Th3 
cells producing high amounts of TGF-β have been implicated as mediators of oral tolerance. 
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The term “Tr1 cells” was proposed for all IL-10-producing regulatory T cell populations that 
are induced by IL-10. Additional subsets of Treg cells may exist as well as additional subsets 
of effector cells, e.g. the more recently described Th9 (Veldhoen et al., 2008, Wong et al., 
2010). In addition, evidence accumulates that there is a significant degree of overlap and 
plasticity between the different subsets of CD4+ T effector and regulatory lymphocytes. 
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Fig. 2. Classical CD4+ T cell subsets and their role in IgE-mediated allergy. Naïve CD4+ T 
lymphocytes differentiate into different subsets directed by cytokines in the 
microenvironment during their activation via the T cell receptor. The presence of high 
concentrations of IL-4 promotes the induction of Th2 cells, IL-12 of Th1 cells, TGF-β Treg 
cells, TGF-β and IL-6 and/or IL-1 Th17 cells and IL-6 and TNF-α Th22 cells. The different 
subsets are characterized by the expression of different transcription factors (GATA-3, T-bet, 
Foxp3, RORγt). The transcription factor of Th22 cells has not yet been identified. Upon 
activation the different subsets of CD4+ effector cells produce different signature cytokines 
and thereby exert different effector functions. 
IgE-mediated disorders result from an aberrant Th2-dominated response to allergens due to 
ineffective counter-regulation by allergen-specific Th1 and Treg cells. The overshooting 
allergen-specific Th2 response promotes the production of allergen-specific IgE antibodies 
which subsequently are bound to the high affinity receptor (FcεRI) on the surface of effector 
cells such as mast cells and basophils (Figure 3). Cross-linking of IgE by allergen induces 
effector cell activation and the release of preformed mediators, most importantly histamine, 
which cause immediate allergic symptoms. After 6-48 hours late phase reactions occur 
which are mediated by eosinophils and allergen-specific T cells that have migrated to the 
site of inflammation. Allergen-IgE-complexes bind to low affinity IgE receptors (FcεRII, 
CD23) expressed on lymphocytes, monocytes, macrophages and platelets. Receptor-
mediated endocytosis of allergens via FcεRII is an important way of allergen uptake by B 
lymphocytes which is thought to increase allergic responses by promoting Th2 responses. 
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Fig. 3. The pathophysiology of IgE-mediated allergy. Allergens enter the human body 
through mucosal sites, e.g. in the respiratory or gastrointestinal tract, or via the skin. 
Antigen-presenting cells, most importantly dendritic cells (DC), take up allergens and 
migrate to lymph nodes where they present allergens to naïve CD4+ T helper (Th) cells. In 
atopic individuals, the majority of allergen-specific T cells differentiate into Th2 cells 
producing high amounts of the signature cytokine IL-4. Interaction of Th2 cells and B cells 
leads to the production of IgE antibodies which are bound on the surface of effector cells. 
Upon repeated allergen encounter, these effector cells are activated and release preformed 
mediators, most importantly histamine, causing immediate allergic symptoms. After 6-48 
hours cell-mediated late phase reactions in target organs can occur because different types 
of granulocytes and allergen-specific T cells have migrated to inflammatory sites. 
3. Birch pollen-related food allergy: Clinical appearance 
Birch pollen is one of the most common causes of rhinoconjunctivitis and allergic asthma in 
Northern and Central Europe and North America (Lin et al., 2002, Stevens et al., 2003). 
Already in 1948 it has been recognized that birch pollen-allergic patients tend to develop 
allergic reactions to fruits and vegetables in addition to seasonal respiratory symptoms 
(Juhlin-Dannfelt, 1948). An association between birch pollinosis and allergic reactions to 
diverse foods was first demonstrated in the late seventies (Hannuksela and Lahti, 1977). In 
this report, more than 380 Finish patients with various atopic disorders were tested for 
allergic reactivity to common fruits and vegetables. Of the patients with hypersensitivity to 
birch pollen, 36% showed immediate positive responses to fresh fruits and vegetables 
whereas such reactions were rare among patients without allergy to birch pollen. One year 
later a correlation between birch pollen allergy and allergic symptoms to nuts, apple, peach, 
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cherry, pear, plum, carrot and new potato was reported in 1120 adult Swedish patients 
(Eriksson, 1978). A subsequent interrogation of 600 patients with pollen allergy again 
confirmed that hypersensitivity to various nuts, fruits and roots was reported more often by 
patients with (70%) than by patients without birch pollen allergy (19%) and that grass pollen 
allergy negatively correlated with food hypersensitivity (Eriksson et al., 1982). 
Approximately, 100 million people suffer from birch pollen allergy worldwide and 
approximately 70% of these individuals develop birch pollen-related food allergy. 
Therefore, this secondary food allergy has to be regarded as one of the most common plant 
food allergies in adolescent and adult individuals today. Interestingly, birch pollen-related 
food allergy is perennial in more than 80% of the affected individuals, i.e. affecting the 
patients also outside of the birch pollen season (Geroldinger-Simic et al., 2011). Around 40% 
of the patients suffer from more severe symptoms during the pollen season as compared to 
the pollen-free time period. The most frequent triggers of birch pollen-related food allergy 
are stone-fruits (apple, peach) and hazelnuts. In addition, particular vegetables (celery, 
carrot), peanuts and soy products can also induce allergic reactions in birch pollen-allergic 
patients (Asero et al., 1996, Eriksson et al., 1982, Geroldinger-Simic et al., 2011, Ghunaim et 
al., 2005, Osterballe et al., 2005). In the majority of patients allergic reactions to these foods 
manifest as contact urticaria of the oral mucosa (oral allergy syndrome, OAS). Typical 
symptoms comprise itching of the lips, tongue and throat, sometimes accompanied by 
oedema of the lips and tongue and occur within minutes after contact with the food 
(Ortolani et al., 1988). Many patients also describe itching in their ears. Usually, these 
reactions disappear within 20-30 minutes. In addition to OAS which is confined to the site of 
allergen exposure, systemic and more severe IgE-mediated reactions such as urticaria, 
asthma or anaphylactic shock may occur occasionally. In particular, the consumption of soy-
containing food products which contain the Bet v 1-homologous protein Gly m 4 have been 
described to trigger anaphylactic reactions such as swollen tongue, angioedema, urticaria, 
rhino-conjunctivitis and/or hypotension within 15-30 min after consumption (Kleine-Tebbe 
et al., 2002, van Zuuren et al., 2010). However, several patients experiencing severe systemic 
reactions to soy-products were found to show IgE-reactivity to seed storage proteins in soy 
which are primary food allergens and also likely candidates to cause the observed severe 
soy allergy (van Zuuren et al., 2010). 
4. Birch pollen-related food allergy: Involved allergens 
Birch pollen contains one major allergen, Bet v 1, which is recognized by IgE antibodies 
from more than 90% of birch pollen-allergic patients (Geroldinger-Simic et al., 2011). Bet v 1 
belongs to the pathogenesis-related (PR) 10 protein family. Other members of this protein 
family have been identified in different foods, such Mal d 1 in apple, Pru p 1 in peach, Pru 
av 1 in cherry, Pyr c 1 in pear, Cor a 1 in hazelnut, Api g 1 in celery, Dau c 1 in carrot, Gly m 
4 in soybean, (all summarized in (Bohle, 2006), Vig r 1 in mungbean (Mittag et al., 2005), Ara 
h 8 in peanut (Mittag et al., 2004), Act d 8 in kiwi (Oberhuber et al., 2008) and jackfruit 
(Bolhaar et al., 2004). Although birch pollen contains additional minor allergens, e.g. Bet v 2 
(birch profilin), that have homologous proteins in various foods, IgE antibodies specific for 
Bet v 1 seem to be most relevant for clinical reactions against birch pollen-related foods since 
a large number of birch pollen-allergic patients with food allergy is exclusively sensitized to 
the major birch pollen allergen (Geroldinger-Simic et al., 2011). 
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The identification of the genes encoding various different Bet v 1-homologs in a great 
variety of food (Table 1) allowed their production as recombinant proteins (Table 1) which 
were employed to analyse structural and immunological characteristics. 
 
Food Bet v 1-homolog GeneBank Acct. No. Sequence identity (%) 
Apple Mal d 1 AJ417551 56 
Hazelnut Cor a 1 AF136945 67 
Nectarine/Peach Pru p 1 DQ251187 73 
Kiwi Act d 8 AM489568 53 
Carrot Dau c 1 AF456481 37 
Apricot Pru ar 1 U93165 56 
Cherry Pru av 1 U66076 59 
Pear Pyr c 1 AF057030 57 
Peanut Ara h 8 AY328088 46 
Celery Api g 1 Z48967 41 
Soybean Gly m 4 X60043 45 
Strawberry Fra a 1 Q256S2 53 
Raspberry Rub I 1 Q0Z8U9 55 
Table 1. Bet v 1-homologs in birch pollen-related foods 
Bet v 1-related food proteins display the typical Bet v 1-fold due to their high amino acid 
sequence similarity with Bet v 1 (Radauer et al., 2008). The highly similar tertiary structure 
explains why IgE-antibodies specific for conformational epitopes of Bet v 1 can cross-react 
with its food homologs. In addition to Bet v 1-specific IgE antibodies, Bet v 1-specific T 
lymphocytes cross-react with related food allergens. This fact has been demonstrated in in 
vitro experiments by employing Bet v 1-specific T cell clones that had been isolated from the 
blood of birch pollen-allergic patients. The clones were stimulated with recombinant Bet v 1-
related food allergens and proliferative and cytokine responses were assessed (Bohle et al., 
2003, Bohle et al., 2005, Fritsch et al., 1998). Several Bet v 1-specific clones proliferated in 
response to different food allergens and produced similar cytokine patterns as compared to 
stimulation with Bet v 1. In particular, T cells specific for the immunodominant T cell-
activating region Bet v 1142-156 which is located in a highly conserved amino acid region of 
the major birch pollen allergen responded to several Bet v 1-related food allergens (Jahn-
Schmid et al., 2005). The cellular cross-reactivity is due to the high amino acid sequence 
similarity between Bet v 1 and its food homologs in this region. In addition to the C-terminal 
T cell epitope located within Bet v 1142-156 (Figure 4), the major birch pollen allergen contains 
other relevant T cell activating regions spreading its entire amino acid sequence (Jahn-
Schmid et al., 2005). Most T cell-activating regions that have been identified in Mal d 1, Cor 
a 1 and Api g 1 match the amino acid sequences of these epitopes (Bohle et al., 2003, Bohle et 
al., 2005, Fritsch et al., 1998). Thereby, the receptor of a Bet v 1-specific T cell can cross-react 
with a peptide derived from antigen-processing of Bet v 1-related food allergens. 
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Fig. 4. Sequence alignment of Bet v 1-related food proteins and Bet v 1. Similar amino acid 
residues are indicated by +. The immunodominant T cell epitope in the C-terminus of Bet v 
1 is underlined. 
Resistance to gastrointestinal degradation and to heat treatment is considered to be an 
important characteristic of food allergens and was investigated by employing recombinant 
Bet v 1-related food allergens. Simulated gastrointestinal degradation of Mal d 1, Api g 1 
and Cor a 1 revealed that these proteins were completely fragmented within a few minutes 
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of exposure to pepsin, the most prominent gastric protease (Kopper et al., 2004, Schimek et 
al., 2005, Schulten et al., 2011). Proteolytic degradation of Bet v 1-homologous food allergens 
into small fragments leads to the loss of their IgE-binding capacity because most IgE-
epitopes of Bet v 1 are conformational epitopes depending on the tertiary protein structure 
(Mittag et al., 2006, Neudecker et al., 2003, Scheurer et al., 1999). The rapid and complete 
degradation of Bet v 1-homologous food allergens explains why systemic IgE-mediated 
reactions rarely occur after consumption of birch pollen-related foods. At the site of contact 
with fresh foods, i.e. the oral mucosa, local IgE-mediated immediate allergic reactions are 
induced by intact food allergens. After swallowing Bet v 1-related food allergens are rapidly 
degraded in the stomach and cannot be absorbed into the blood stream in a form capable of 
inducing IgE-mediated effector cell activation. As a consequence, systemic allergic reactions 
to birch pollen-related foods are rare. However, there are exceptions to this process, for 
example, the so-called “bio-bar syndrome”. This syndrome describes occasional 
anaphylactic reactions in patients with birch pollen allergy that occur after the consumption 
of fruit and vegetable smoothies. These drinks are usually prepared from fresh apple 
and/or raw carrot and drunk very rapidly at so-called bio-bars. We recently found a 
possible explanation for this phenomenon by performing  in vivo absorption assays in an 
animal model (Schulten et al., 2011). We observed that the pH value in the stomach of rats 
rises to 5 after allergen administration. Similarly, administration of a peanut-based meal 
initially neutralized the gastric pH value of piglets to approximately 7, which was 
subsequently acidified by HCl secretion (Kopper et al., 2006). The high pH value renders 
pepsin inactive. Consequently, Bet v 1-homologous food allergens were not degraded by the 
protease and could be detected in the rat serum after a time period of 2 hours (Schulten et 
al., 2011). Deduced from these in vivo results from animal models we propose that rapid 
drinking of freshly prepared smoothies on an relatively empty stomach of birch pollen-
allergic individuals will rise the gastric pH value and prevent immediate pepsinolysis of 
food allergens. Thereby, a dose of IgE-reactive Bet v 1-related food allergens can be 
absorbed which is sufficient to subsequently cause systemic anaphylaxis. The same cascade 
of events may also explain the severe anaphylactic reactions observed in birch pollen-
allergic patients after ingestion of soy-based foods, in particular soy milk, containing the Bet 
v 1-homolog Gly m 4 (Kleine-Tebbe et al., 2002). 
Recombinant Bet v 1-related food allergens were also employed to investigate the effects of 
heat treatment on these proteins. Exposure to high temperatures demolishes their 3-
dimensional structure, thereby reducing their capacity to bind IgE and consequently, to 
induce IgE-mediated effector cell activation (Bohle et al., 2006). This biochemical behaviour 
explained why typically, only fresh fruits and vegetables induce immediate allergic 
symptoms whereas cooked birch pollen-related foods are usually tolerated by birch pollen-
allergic patients. 
In summary, Bet v 1-related food allergens lack typical features of primary food allergens, 
i.e. resistance to gastrointestinal degradation and heat treatment. Therefore, they are 
considered to be secondary or incomplete food allergens, i.e. incapable of initiating an 
allergic sensitization in an individual by themselves. However, due to their structural 
similarity with Bet v 1 and to the high amino acid sequence identity between the major birch 
pollen allergen and its dietary homologs these proteins can induce allergic symptoms when 
cross-reactive Bet v 1-specific IgE antibodies and T cells are present in allergic patients. IgE-
mediated symptoms appear as OAS immediately after contact with the respective fresh 
foods in the majority of patients. The activation of Bet v 1-specific T cells by Bet v 1-related 
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food allergens may induce late phase responses in target organs in a minority of birch 
pollen-allergic patients, for example a worsening of atopic eczema occurring 12-48 hours 
after consumption of birch pollen-related foods (Bohle et al., 2006, Werfel et al., 1999). In 
biopsies of such flare ups Bet v 1-specific T cells have been detected (Reekers et al., 1999). 
This finding indicated that after ingestion and gastrointestinal proteolysis of Bet v 1-related 
food allergens fragments thereof were absorbed into the blood and induced the activation of 
Bet v 1-specific T cells. Indeed, several fragments of Bet v 1-homologous food allergens were 
identified after simulated gastrointestinal degradation that contained T cell activating 
regions and induced the proliferation and cytokine synthesis of Bet v 1-specific T cell clones 
in vitro (Schimek et al., 2005). In vivo, Bet v 1-specific T lymphocytes activated by such cross-
reactive peptides may migrate into target organs such as the skin and exert local effector 
functions, e.g. a worsening of atopic eczema. 
Of note, T cell-mediated symptoms induced by Bet v 1-related food allergens can occur 
independently from IgE-mediated reactions. This means that patients who do not 
experience an OAS when consuming birch pollen-related foods may still suffer from flare-
ups of their atopic eczema several hours after ingestion. For example, when birch pollen-
allergic patients were challenged with cooked birch pollen-related foods, these individuals 
did not experience immediate symptoms but T cell-mediated late phase reactions  (Bohle et 
al., 2006). Together, biochemical and immunological data gained with recombinant Bet v 1-
homologous food allergens provide an explanation for this clinical observation. Allergen-
recognition differs between IgE antibodies and allergen-specific T cells. In contrast to IgE 
antibodies which often recognize conformational epitopes depending on the tertiary 
structure of an allergen T cells recognize small linear peptides generated during antigen 
processing of proteins (Figure 5). Cooking of Bet v 1-homologs leads to their loss of IgE-
binding. Nevertheless, heat-denatured Bet v 1-related food allergens are taken up and 
processed by antigen-presenting cells and thereafter, presented to T lymphocytes. 
 
N
COOH
Y
N
COOH
N-ALYANLEPKAEQPTEKITKVFGDEAEEVLKYL-COOH N-ALYANLEPKAEQPTEKITKVFGDEAEEVLKYL-COOH  
Fig. 5. Antigen-recognition by B and T lymphocytes. Antibodies (indicated as Y) produced 
by plasma cells often recognize conformational epitopes that depend on the tertiary 
structure of proteins. The amino acid residues forming the epitope are not neighbouring 
residues in the primary sequence. In contrast, linear T cell epitopes highlighted as black 
lines within the amino acid sequence consist of neighbouring amino acid residues. 
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What may be the consequence of T cell activation by ingested Bet v 1-related food allergens? In 
allergic individuals, allergen-specific T cells were shown be long-lived and to exist for several 
years (Bohle et al., 1998, Wedderburn et al., 1993). In order to survive, specific memory T cells 
seem to require repeated contact with antigen. The ingestion of pollen-related food proteins 
capable of activating pollen-specific T lymphocytes may represent one way to stimulate these 
cells, in particular outside of the tree pollen season. In our studies the majority of the food 
allergen-reactive Bet v 1-specific TCC were Th2-like and synthesized high levels of IL-4 in 
response to the food allergens (Bohle et al., 2003, Bohle et al., 2005, Fritsch et al., 1998). 
Therefore, the perennial uptake of pollen-related food could stimulate the survival of T cells 
and ongoing IL-4 synthesis and thereby contribute to the typical maintenance of high levels of 
pollen-specific IgE also outside of the tree pollen season. A summary of the consequences of 
consumption of Bet v 1-related food allergens is provided in Figure 6. 
5. Bet v 1 is the primary sensitizer in birch pollen-related food allergy 
Clinical, immunological and biochemical data support that birch pollen-related food allergy 
is a secondary food allergy and results from primary respiratory sensitization to the major 
birch pollen allergen and subsequent immunological cross-reactivity. From the clinical point 
of view, the majority of patients develop food-induced allergic symptoms after the onset of 
respiratory allergy (Geroldinger-Simic et al., 2011). Furthermore, a high number of birch 
pollen-allergic patients shows IgE-reactivity to Bet v 1-related food allergens without 
developing clinical reactions to the respective foods whereas only very few food-allergic 
individuals display IgE-reactivity to Bet v 1-homologous food allergens in the absence of Bet 
v 1-specific IgE antibodies (Flinterman et al., 2006, Moneo et al., 1999). Finally, patients 
suffering from allergic reactions to stone-fruits and hazelnuts in birch-free areas are not 
sensitized to Bet v 1-homologous food allergens but to other plant food allergens, e.g. non-
specific lipid transfer proteins (Fernandez-Rivas et al., 2008, Fernandez-Rivas et al., 2006). 
Immunologically, Bet v 1 not only cross-reacts with its related dietary proteins but the major 
birch pollen allergen dominates the IgE and T cell reactivity to its homologs. For example, 
pre-incubation of patients´ sera with Bet v 1 totally abolishes their IgE-binding to Mal d 1 
and Api g 1 whereas pre-incubation of the same sera with Bet v 1-related food allergens 
reduces IgE-binding to the major birch pollen allergen to only around 50% (Bohle et al., 
2003, Kinaciyan et al., 2007). These experimental findings indicate that Bet v 1 contains most 
IgE-epitopes of its food homologues and binds IgE with higher affinity. Thus, it may be 
concluded that Bet v 1 initiated the production of specific IgE antibodies in vivo. Similar to 
the IgE level, experimental in vitro approaches revealed that Bet v 1 dominates the T cell 
response to its food-homologs. When T cells reactive with Bet v 1-related food allergens 
were isolated from the peripheral blood of allergic patients and re-stimulated with either the 
food allergen or Bet v 1, most cultures responded stronger to the major birch pollen allergen 
(Bohle et al., 2003, Bohle et al., 2005, Fritsch et al., 1998). This finding indicates that T cells 
which respond to stimulation with Bet v 1-related food allergens are cross-reactive, Bet v 1-
specific clonotypes. Again, these observations support that Bet v 1 was the initial stimulus 
for an allergic response in birch pollen-related food allergy. 
Biochemically, the high susceptibility of Bet v 1-homologous dietary allergens to proteolytic 
degradation in the stomach and small intestine prevents them from reaching the gut-
associated lymphoid tissue (GALT) in an intact form. Therefore, Bet v 1-homologous food 
allergens are considered to be incapable of sensitizing an individual by themselves after 
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being taken up through their natural route of exposure. In contrast, the major birch pollen 
allergen is inhaled and thereby not exposed to the harsh conditions of the gastrointestinal 
tract. Bet v 1 reaches the respiratory tract in an immunological active form where it can 
induce IgE-production. Together, clinical and experimental observations support that the 
major birch pollen allergen is the primary sensitizer in birch pollen-related food allergy. 
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Fig. 6. Proposed pathophysiology of pollen-related food allergy. Bet v 1 initiates respiratory 
sensitization. Bet v 1-specific IgE antibodies recognize structurally related dietary proteins in 
various foods which may cause clinical reactions, often directly at the site of allergen contact, 
e.g. the oral mucosa. After ingestion Bet v 1-related food homologs are degraded when passing 
through the intestinal tract. Cooking of the respective foods also denatures Bet v 1-related food 
allergens. The destruction of their 3-dimensional structure leads to the loss of IgE-binding 
capacity of Bet v 1-homologous food proteins. Nevertheless, allergenic fragments after 
gastrointestinal degradation as well as heat-denatured Bet v 1-related allergens are still 
capable of activating Bet v 1-specific T lymphocytes. Upon activation, Bet v 1-specific T cells 
proliferate and produce cytokines. They also migrate to different target organs where they 
may exert clinical late-phase reactions, e.g. the worsening of atopic eczema in the skin. 
Possibly, activation of pollen-specific Th2 cells by ingested food proteins also contributes to 
their survival and longevity in allergic patients. 
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Interestingly, a few food-allergic patients have been identified to bear IgE antibodies specific 
for Bet v 1-related food allergens, e.g. Cor a 1 in hazelnut, without being sensitized to the 
major birch pollen allergen (Flinterman et al., 2006). This finding suggested that a non-pollen-
related route of sensitization to the Bet v 1-homologous hazelnut allergen may be possible. 
Along these lines, we previously found evidence for a potential sensitizing capacity of Cor a 1 
based on the identification of T cell clones that did not cross-react with Bet v 1 (Bohle et al., 
2005). However, in simulated gastrointestinal degradation assays pure Cor a 1 lost its IgE-
binding ability within a few seconds of incubation with pepsin (Schimek et al., 2005). This 
discrepancy tempted us to investigate whether the natural matrix embedding Cor a 1 may 
contribute to its sensitizing capacity. Actually, in simulated gastrointestinal degradation 
assays, we found that the presence of hazelnut extract protected Bet v 1-related food allergens 
from gastric proteolysis (Schulten et al., 2011). Since Cor a 1 has been demonstrated to be 
relatively resistant to simulated degradation by the intestinal protease trypsin (Schimek et al., 
2005) we conclude that hazelnuts which provide a food matrix rich in carbohydrates and 
proteins under certain circumstances may contribute to a sensitizing capacity of the major 
hazelnut allergen independently from respiratory sensitization to Bet v 1. Most patients 
showing IgE-reactivity to Cor a 1 but not to Bet v 1 were children (Flinterman et al., 2006). 
Therefore, the still immature gastrointestinal tract of children may be such an additional 
precondition for a possible sensitization to Cor a 1. 
6. Treatment strategies for birch pollen-related food allergy 
6.1 Specific immunotherapy with birch pollen 
Together, clinical and immunological observations provide strong evidence that birch 
pollen-related food allergy is a consequence of cross-reactivity between Bet v 1 and its 
dietary homologs. Thus, one would assume that successful allergen-specific 
immunotherapy (SIT) of birch pollen allergy might concomitantly cure birch pollen-related 
food allergy. SIT consists of a series of continuous administration of increasing doses of 
allergen extracts to the allergic patient in order to induce clinical tolerance (1993) and is 
currently the only causative treatment for IgE-mediated allergy that results in long-term 
clinical tolerance to allergens. Various studies have shown that successful SIT alters the 
allergen-specific immune response (Larche et al., 2006). In general, SIT induces high levels of 
allergen-specific IgG antibodies, in particular IgG4, which are considered as “blocking” 
antibodies because they compete with IgE for allergen-binding and thereby impair IgE-
mediated reactions, e.g. allergen-induced activation of basophils and mast cells or IgE-
facilitated allergen uptake and presentation to T cells (James et al., 2011, Nouri-Aria et al., 
2004, van Neerven et al., 1999, Wachholz et al., 2003). At the T cell level it has been 
demonstrated that SIT induces a shift from the disease-eliciting T helper (Th) 2- towards a 
Th1-like response and regulatory CD4+ T (Treg) cells that actively suppress proliferation 
and cytokine production of allergen-specific effector T cells (Akdis et al., 1998, 
Bellinghausen et al., 1997, Ebner et al., 1997, Jutel et al., 2003). In addition to the modulation 
of the adaptive immune response to allergens, SIT also modulates the function of APC and 
effectors cells (Larche et al., 2006), e.g. reduction of the number of mast cells and their ability 
to release mediators. The recruitment of eosinophils and neutrophils to sites of allergen 
exposure is also reduced during SIT. 
An overview on the immune mechanisms operative during successful SIT is given in Figure 
7. However, it is still not clear which of these immune mechanisms actually translate(s) into 
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clinical tolerance of patients, i.e. improvement of symptoms, and whether one or more of 
these mechanisms fail those individuals who are not cured by SIT. 
SIT with birch pollen has been proven efficient for the treatment of birch pollinosis (Bodtger 
et al., 2002, Cirla et al., 1996, Winther et al., 2000). However, the clinical benefit of SIT with 
birch pollen on birch pollen-related food allergy is still debated. Whereas a few studies have 
described that patients improved their clinical symptoms to birch pollen-related foods after 
birch pollen-SIT (Asero, 1998, 2003, 2004) others have reported limited curative effects of 
birch pollen-SIT on birch pollen-related food allergy and some patients even developed 
allergic reactions to foods during the course of therapy (Bucher et al., 2004, Herrmann et al., 
1995, Modrzynski et al., 2002, van Hoffen et al., 2011). It has to be stressed that at present a 
prospective study investigating food allergic reactions in a sufficient number of birch 
pollen-allergic patients before and during birch pollen-SIT by means of double-blind 
placebo controlled food challenges (DBPCFC) is lacking. Nevertheless, the majority of 
clinicians observe that only approximately one third of birch pollen-allergic patients 
undergoing birch pollen-SIT concomitantly improve birch pollen-related food allergy. Thus, 
no effective treatment for this secondary food allergy exists at present. However, because of 
its high prevalence and the impaired quality of life of the affected individuals, there is a 
need for an efficient treatment strategy for birch pollen-related food allergy. 
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Fig. 7. Immune mechanisms operative during allergen-specific immunotherapy (SIT). An 
overshooting allergen-specific Th2 response causes allergic diseases. Th2 cells produce IL-4 
that triggers B cells to produce allergen-specific IgE antibodies. Th2 cells also synthesize IL-
5, which activates eosinophils. IgE and eosinophils mediate the immediate allergic response. 
SIT induces immune deviation, i.e. the switch from Th2 towards Th1-like cells which 
produce high levels of IFN-γ,  a potent antagonist of IL-4. SIT also promotes the induction of 
regulatory T (Treg) cells which produce IL-10 and/or TGF-β. These immunosuppressive 
cytokines induce the production of allergen-specific IgG4 and IgA antibodies which may 
compete with IgE for allergen-binding (“blocking antibodies”. IL-10 promotes further 
induction of regulatory T cells. 
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Sublingual immunotherapy (SLIT) has been demonstrated to be an effective and safe 
alternative for conventional subcutaneous SIT of birch pollen allergy (Horak et al., 1998, 
Khinchi et al., 2004, Mauro et al., 2007). Similar to subcutaneous immunotherapy SLIT 
induces allergen-specific IgG1 and IgG4 antibodies and a modulation of the allergen-specific 
T cell response (O'Hehir et al., 2009, Scadding et al., 2010). Moreover, SLIT induced 
increased Foxp3+  cells - presumably regulatory T cells - in the sublingual epithelium 
(Scadding et al., 2010). Speculating that sublingual administration, directly at the site of 
food-induced allergic symptoms, instead of subcutaneous injections might improve the 
therapeutic benefit on birch pollen-related food allergy, we have evaluated the effects of 
SLIT with birch pollen extract on apple allergy in birch pollen-allergic individuals 
(Kinaciyan et al., 2007). The clinical efficacy of birch pollen SLIT was assessed by means of 
nasal provocation tests with birch pollen extract and double-blind placebo-controlled food 
challenges with Golden Delicious apples before and after 1 year of treatment. Nine patients 
improved in nasal provocation tests to birch pollen and were therefore considered as 
successfully treated. However, only very few of the nine patients concomitantly improved 
allergic reactions to apple in double-blind placebo-controlled food challenges. To 
understand this limited curative effect of birch pollen-SLIT on associated apple allergy, Bet 
v 1- and Mal d 1-specific antibody and T cell responses were analysed in the successfully 
treated individuals. All patients developed significantly increased Bet v 1-specific IgG4 
antibody levels after 1 year of SLIT. Interestingly, Mal d 1-specific IgG4 antibody levels did 
not increase significantly in parallel (Kinaciyan et al., 2007). At the T cell level, a significant 
reduction of Bet v 1-specific T cell proliferation after 4 and 52 weeks of SLIT was found 
(Bohle et al., 2007). This reduced allergen-specific T cell response could be referred to the 
induction of IL-10-producing regulatory T cells in the early phase and the switch from Bet v 
1-specific Th2 cells towards more Th1 cells in the late phase of SLIT. However, no similar 
modulation of the Mal d 1-specific T cell response was observed. Together, these findings 
suggested that birch pollen SLIT induced the characteristic immune mechanisms operative 
during SIT, such as blocking antibodies, peripheral tolerance, regulatory T cells and immune 
deviation, specific for Bet v 1 but not for its highly cross-reactive homologue in apple. Along 
these lines, a more recent study demonstrated that conventional subcutaneous SIT with 
birch pollen also failed to induce food-reactive IgG4 antibodies (van Hoffen et al., 2011). The 
sera from 10 birch pollen-allergic patients with associated allergy to hazelnut were 
investigated for Bet v 1- and Cor a 1-specific IgG4 antibodies before, after 3, 6, 9 and 12 
months of birch pollen-SIT. Again, the significant increase of Bet v 1-specific IgG4 antibody 
titers was not paralleled by a significant increase of Cor a 1-reactive IgG4 antibody levels. 
Nevertheless, after three months of treatment the sera contained significantly enhanced Cor 
a 1-reactive IgG levels and the sera obtained after 1 year of treatment showed IgE-blocking 
capacity in facilitated antigen-binding (FAB) assays (Shamji et al., 2006). Still, SIT with birch 
pollen extract did not result in clinical improvement of hazelnut allergy in these patients as 
analyzed by means of double-blind placebo-controlled food challenges at inclusion and after 
1 year of treatment (van Hoffen et al., 2011). 
Together, these studies imply that the limited clinical effect of SIT with birch pollen may be 
due to a failure of the induction of cross-reactive IgG and T cell responses. However, it 
needs to be pointed out that so far in relatively low numbers of birch pollen-allergic 
individuals were assessed for their antibody and T cell responses to Bet v 1-homologous 
food allergens during birch pollen-SIT or SLIT. Therefore, we analysed IgG responses 
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specific for Bet v 1, Mal d 1 and Cor a 1 in sera from 49 patients who received birch pollen 
SIT for 1-3 years and developed Bet v 1-specific IgG4 antibodies. Interestingly, only around 
33% of these individuals developed food-reactive IgG4 antibodies. Food-reactive antibodies 
in general increased later during the course of therapy as compared to Bet v 1-specific IgG4 
antibodies and blocked IgE binding to Bet v 1-related food allergens. Similarly, only a 
limited number of birch pollen-allergic patients developed food-reactive IgG1 antibodies 
after subcutaneous administration of a recombinant hypoallergenic variant of Bet v 1 
(Niederberger et al., 2007). In a recent study including more than 200 birch pollen-allergic 
individuals we observed that patients tolerating birch pollen-related foods showed higher 
ratios of serum allergen-specific IgG4/IgE antibody levels than patients with food allergy 
(Geroldinger-Simic et al., 2011). These naturally occurring allergen-specific IgG4 antibodies 
were capable of blocking IgE-binding to Bet v 1-related food allergens. These data indicate 
that the presence of allergen-specific IgG4 antibodies which compete with IgE for allergen-
binding may be important for the development of food tolerance. Therefore, SIT or SLIT 
should induce such antibodies. However, treatment with birch pollen does not effectively 
induce food-reactive IgG4 antibodies in every patient. Therefore, we propose that vaccines 
for the treatment of birch pollen-related food allergy should contain the disease-eliciting 
food allergens. Previously, a randomized, double-blind, placebo-controlled study has 
demonstrated significant increases in tolerance to hazelnut after sublingual administration 
of hazelnut extract (Enrique et al., 2005). Tolerance induction was accompanied by increased 
IgG4 antibody and IL-10 levels after immunotherapy in only the active group. Thus, SLIT 
with Bet v 1-associated food allergens may be a promising approach for treatment of birch 
pollen-related food allergy. 
Finally, it is an interesting immunological finding that a high number of birch pollen-allergic 
patients show food-reactive Bet v 1-specific IgE antibodies but fail to develop cross-reactive 
IgG antibodies during treatment with birch pollen despite developing high levels of Bet v 1-
specific IgG antibodies. Therefore, birch pollen-related food allergy is an interesting model 
to study the question how cross-reactivity of structurally related allergens can cause allergy 
whereas the immunomodulation of the allergen-specific response in SIT-treated patients 
who improve their pollinosis does not concomitantly translate into clinical tolerance to 
associated foods. 
6.2 Future concepts for treatment of birch pollen-related food allergy 
Although rarely life-threatening birch pollen-related food allergy is highly prevalent and 
often causes perennial discomfort. Furthermore, this secondary food allergy prevents birch 
pollen-allergic patients from consuming a great variety of fresh fruits and vegetables which 
contain vitamins and are considered to be healthy. This situation demands for effective 
treatment which at present does not exist. Recent developments in the treatment of food 
allergy suggest oral immunotherapy (OIT) with the disease-eliciting food as an interesting 
option (Nowak-Wegrzyn and Sampson, 2011). Indeed, results from a double-blind placebo 
controlled study in peanut-allergic children demonstrated that OIT with peanut induced 
desensitization and concurrent immune modulation (Varshney et al., 2011). In contrast to 
the placebo group, the actively treated OIT group showed significant reductions in skin 
prick reactivity to peanut and significant increases in peanut-specific IgG4 antibodies. 
Furthermore, the ratio of FoxP3hi: FoxP3intermediate CD4+CD25+ T cells increased in peanut 
OIT subjects suggesting the induction of regulatory T cells. Similar approaches might be 
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feasible for the treatment of birch pollen-related food allergy. Recently, it was observed that 
continuous consumption of small amounts of apple induces clinical tolerance in birch 
pollen-allergic patients with apple allergy (Kopac et al., 2010). In this study, 21 patients daily 
consumed small amounts of apple, doubling the dose every two weeks. After a regular 
exposure of in average 22 weeks, 16/21 patients tolerated a complete apple without 
developing any signs of an OAS. This desensitization was paralleled by a decrease of 
intradermal reactivity to Mal d 1. This preliminary study indicates that OIT may be a 
possible approach to treat birch pollen-related apple allergy. 
Novel concepts for allergy vaccines for SIT include the use of recombinant allergens instead 
of crude extracts containing a mixture of allergenic and non-allergenic proteins of an 
allergen source (Valenta et al., 2011). Although progress has been made to improve the 
quality and standardization of protein extracts the use of allergen extracts for SIT still bears 
some disadvantages. The complex protein mixture makes it difficult to determine the exact 
content of single allergens. Due to the production process the concentration of individual 
allergens may vary between different batches. Highly labile allergens might even be totally 
lost during the production process and not be present in the extract. The availability of 
recombinant allergens with the same immunological characteristics as their natural 
counterparts can overcome several of these disadvantages. Briefly, recombinant allergens 
can be produced as molecules with known molecular, immunologic and biological 
characteristics in consistent quality and unlimited amounts. Thus, the content of individual 
allergens in a vaccine can precisely be formulated and the potential loss of allergens 
destroyed during the production process of allergen extracts can be excluded. Regarding the 
treatment of birch pollinosis, recombinant Bet v 1 has been demonstrated to be as effective 
as birch pollen extract (Pauli et al., 2008). As discussed above, we propose that vaccines for 
the treatment of birch pollen-related food allergy should contain the disease-eliciting dietary 
allergens. Bet v 1-related proteins are known to be easily degraded during the procedures 
applied for the production of protein extracts. Since the most important and frequently 
recognized Bet v 1-related food allergens are available as recombinant proteins (Table 1), 
these proteins should be employed as active component in future vaccines for SIT or SLIT of 
birch pollen-related food allergy. 
In addition to producing well-defined batches of recombinant wild-type allergens with 
identical features to their natural counterparts, the recombinant DNA technology also offers 
the possibility to selectively modify certain properties and functions of allergenic proteins 
(Mutschlechner et al., 2009). Diverse modifications of allergens can be genetically 
engineered, e.g. variants with reduced IgE-binding capacity, multi-mers of single allergens 
or hybrids consisting of different allergens. Furthermore, allergens can be genetically fused 
with proteins that promote immune responses which counter regulate the disease-eliciting 
Th2-dominated immune response in allergic individuals and may therefore, improve the 
efficacy of SIT (Bohle et al., 2004, Gerstmayr et al., 2007). All these approaches may also be 
employed to develop an effective treatment strategy for birch pollen-related food allergy. 
We have recently sublingually administered recombinant Mal d 1 to 18 birch pollen-allergic 
patients with associated apple allergy. The recombinant apple allergen was well tolerated by 
the individuals and no severe side-effects were observed. This approach may be regarded as 
a first proof-of-concept for the applicability of recombinant Bet v 1-related food allergens for 
SLIT.  Certainly, several questions regarding the optimum content of a vaccine to treat birch 
pollen-related food allergy remain open. Most patients react to more than one food and it 
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remains to be determined whether all individual food allergens should be employed for 
treatment. Moreover, it remains to be investigated whether the vaccine should contain food 
allergens with or without Bet v 1. 
7. Conclusion 
Birch pollen-related food allergy is a relevant allergic disease that affects the vast majority of 
birch pollen-allergic patients and strongly impairs their quality of life. Currently, no 
effective therapy for this form of food allergy is available. The detailed investigation of the 
allergic response to Bet v 1-homologous food allergens has provided evidence that birch 
pollen-related food allergy results from immunological cross-reactivity of the major birch 
pollen allergen and structurally related dietary proteins. However, it is somehow 
astonishing that successful SIT or SLIT of birch pollinosis accompanied by the modulation of 
the Bet v 1-specific immune response does not effectively cure birch pollen-associated food 
allergy in parallel. Primary sensitization to the major birch pollen allergen and subsequent 
cross-reactivity can cause food allergy. However, the immunomodulation of Bet v 1-specific 
antibody and T cell responses during SIT with birch pollen does not concomitantly 
modulate reactivity to the respective food allergens. Thus, birch pollen-related food allergy 
is an interesting model to learn more about the consequence of immunological cross-
reactivity between related allergens in different sources. The detailed analysis of the 
immune mechanisms failing in patients who do not improve pollen-associated food allergy 
during SIT with birch pollen will help to improve the treatment and to develop an efficient 
therapy for birch pollen-related food allergy. 
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